Viking Therapeutics, Inc.
VKTX
Clasificación en acciones
#4539
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Precio por acción
$26.41
Capitalización bursátil
$3.36B
Cambio (1 día)
-1.12%
Cambio (1 año)
-19.92%
País
US
Comercio Viking Therapeutics, Inc. (VKTX)
Categoría
Healthcare
Historial de desdoblamientos de acciones de Viking Therapeutics, Inc. (VKTX)
La acción Viking Therapeutics, Inc. (símbolo: VKTX) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Oct 21, 2026.
Una acción VKTX comprada antes de Oct 21, 2026 equivaldría hoy a 0 acciones VKTX.
El desdoblamiento más reciente ocurrió el Oct 21, 2026.
Una acción VKTX comprada antes de Oct 21, 2026 equivaldría hoy a 0 acciones VKTX.
Lista de desdoblamientos de acciones
| Año | Desdoblamiento | Multiplicador | Multiplicador acumulado |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Desdoblamientos de acciones de empresas similares o competidoras
| Empresa | Número de desdoblamientos de acciones | Multiplicador acumulado | País |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|